Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Literature DB >> 9365166

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

J van Asperen¹, O van Tellingen, A Sparreboom, A H Schinkel, P Borst, W J Nooijen, J H Beijnen.

Abstract

Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results encourage further research on the development of a clinically useful oral formulation of paclitaxel.

Entities: Chemical Species

Mesh：

Substances：

Year: 1997 PMID： 9365166 PMCID： PMC2228133 DOI： 10.1038/bjc.1997.530

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

16 in total

1. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.

Authors: J M Croop; M Raymond; D Haber; A Devault; R J Arceci; P Gros; D E Housman
Journal: Mol Cell Biol Date: 1989-03 Impact factor: 4.272

2. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

Authors: D Boesch; C Gavériaux; B Jachez; A Pourtier-Manzanedo; P Bollinger; F Loor
Journal: Cancer Res Date: 1991-08-15 Impact factor: 12.701

3. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Authors: A Sparreboom; J van Asperen; U Mayer; A H Schinkel; J W Smit; D K Meijer; P Borst; W J Nooijen; J H Beijnen; O van Tellingen
Journal: Proc Natl Acad Sci U S A Date: 1997-03-04 Impact factor: 11.205

4. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.

Authors: J L Eiseman; N D Eddington; J Leslie; C MacAuley; D L Sentz; M Zuhowski; J M Kujawa; D Young; M J Egorin
Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333

5. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.

Authors: R P Keller; H J Altermatt; K Nooter; G Poschmann; J A Laissue; P Bollinger; P C Hiestand
Journal: Int J Cancer Date: 1992-02-20 Impact factor: 7.396

6. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.

Authors: M S Shet; C W Fisher; P L Holmans; R W Estabrook
Journal: Proc Natl Acad Sci U S A Date: 1993-12-15 Impact factor: 11.205

7. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Authors: A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele
Journal: Cell Date: 1994-05-20 Impact factor: 41.582

8. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme.

Authors: J W Harris; A Rahman; B R Kim; F P Guengerich; J M Collins
Journal: Cancer Res Date: 1994-08-01 Impact factor: 12.701

Review 9. Paclitaxel (taxol)

Authors: E K Rowinsky; R C Donehower
Journal: N Engl J Med Date: 1995-04-13 Impact factor: 91.245

10. [Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level].

Authors: H Fujita; M Okamoto; A Takao; H Mase; H Kojima
Journal: Gan To Kagaku Ryoho Date: 1994-04

32 in total

Review 1. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors: Margaret M Doherty; William N Charman
Journal: Clin Pharmacokinet Date: 2002 Impact factor: 6.447

Review 2. Oral delivery of taxanes.

Authors: M M Malingré; J H Beijnen; J H Schellens
Journal: Invest New Drugs Date: 2001-05 Impact factor: 3.850

Review 3. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors: H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal: Invest New Drugs Date: 2000-08 Impact factor: 3.850

4. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

Authors: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Journal: Invest New Drugs Date: 2004-08 Impact factor: 3.850

Review 5. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors: Y Zhang; L Z Benet
Journal: Clin Pharmacokinet Date: 2001 Impact factor: 6.447

6. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors: Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal: J Cancer Res Clin Oncol Date: 2007-10-12 Impact factor: 4.553

7. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors: Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal: J Clin Invest Date: 2002-11 Impact factor: 14.808